Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Combining the Past, Present & Future: Learnings, Trends & Impact of the Past 10 Years of ADC Combination Therapies

By | 8 June 2026

Giving a retrospective view to highlight the growth and make-up of ADC combinations over the past ten years
Understanding the highs and lows of ADC combinations: What has been the most impactful to patients?
Evaluating the current landscape and future directions of ADC combinations to combat payload resistance and push ADCs to earlier line therapies